Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the "perfect pairing" of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.
此公司進入各市場的次序 — 由最舊至最新
註冊以查看完整訊號動態
Clarity Pharmaceuticals 的國際擴張與競爭對手的比較
Clarity Pharmaceuticals你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Clarity Pharmaceuticals你 | 0 | 0 | 0% | 0 | 32 |
Head of Clinical Development
查看招聘Sydney, New South Wales, Australia · 3星期前
Senior Manager, People & Culture
查看招聘United States · 4個月前
Clinical Data Analyst and Statistical Programmer
查看招聘Sydney, New South Wales, Australia · 4個月前
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
Clarity Pharmaceuticals的67Cu-SAR-bisPSMA前列腺癌SECuRE試驗完成劑量遞增，顯示有希望的療效和安全性，並進入二期擴展。
Clarity Pharmaceuticals 開始 SECuRE 試驗的隊列擴展階段，首次使用 67Cu-SAR-bisPSMA 治療轉移性去勢抵抗性前列腺癌患者。
Clarity製藥公司開始64Cu-SAR-bisPSMA的第三期試驗，用於檢測前列腺癌復發，旨在獲得FDA批准作為診斷劑。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Clarity Pharmaceuticals 業務、市場及增長訊號的快速解答。
